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Angiogenesis is the growth of new blood vessels from a pre-existing vasculature. The 
deregulation of this physiological process is involved in several pathologies including cancer 
and inflammatory diseases (atherosclerosis, rheumatoid arthritis or age-related macular 
degeneration). Consequently, the research for drugs able to disrupt abnormal angiogenesis 
constitutes an essential research field [1].  
Angiogenic sprouting of blood vessels depends on the balance between pro- and anti-
angiogenic molecules. Among them, the vascular endothelial growth factor (VEGF A) is the 
major contributor to tumor angiogenesis [2]. The predominant isoform of VEGF A in humans 
is named VEGF165, according to its length in amino acids. VEGF165 pro-angiogenic activity 
is mediated through binding to two high-affinity tyrosine kinase receptors: VEGF receptor 1 
(VEGF-R1, Flt-1) and VEGF receptor 2 (VEGF-R2, KDR), located predominantly at the 
surface of endothelial cells but also on several tumour cell lines [3]. Neuropilin-1 (NP-1), a 
non-tyrosine kinase receptor of VEGF165, acts as a co-receptor, enhancing the activity of 
VEGF-R2 [4]. The specific role of VEGF-R1 is still a matter of debate. It acts as a negative 
regulator of angiogenesis during development but an increasing number of papers tend to 
demonstrate its specific implication as a promoter of angiogenesis under pathological 
conditions [5]. 
 Considering the central role displayed by the system VEGF165/VEGF-R1 in disease-
associated angiogenesis, it constitutes an attractive target for the development of anti-
angiogenic therapies. Among the several strategies developed to disrupt this interaction, a 
promising approach is constituted by antagonist molecules, with a high affinity for the 
extracellular domain of the receptor, able to prevent VEGF165 binding on VEGF-R1 [6].  
The affinity of these molecules is commonly evaluated thanks to a radioactive 
competition test: the tested compound and radiolabeled [125I]VEGF165 are incubated with 
cells expressing VEGF receptors [7], membranes from endothelial cells [8] or directly with 
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recombinant receptors coated on microplates [9], and the remaining activity after washes is 
measured. Unfortunately, the increasing logistical and regulatory difficulties associated with 
the use of radioactive isotopes threaten to limit the usefulness of this method. Consequently, 
the discovery of antagonists is limited by the unavailability of a safe and low-cost high-
throughput screening test, and therefore, few antagonists have been reported to date [6]. To 
help in the discovery of potential new antiangiogenic therapeutics, we have developed a 
robust non-radioactive assay system for screening of VEGF receptors ligands. Our test is 
based on competition between compounds and biotinylated VEGF165 (btVEGF165), which is 
detected by chemiluminescence (Fig. 1). This test is performed with the extra-cellular domain 
(ECD) of recombinant human VEGF-R1, allowing the discovery of receptor-specific 
molecules. Indeed, cell lines over-expressing one of the receptors proved to be not always a 
reliable system for testing ligand specificity due to the constitutive co-expression of other 
receptors, as attested by Perret et al who described for the first time a VEGF-R2 specific 
antagonist whose biological effect was in fact triggered by interaction with NP-1 [7, 10]. 
 In a first step, we determined the affinity of btVEGF165 for VEGF-R1 ECD. The 
surface of white high binding 96-well microplates (Corning Life Sciences, Netherlands) was 
coated with 100 μl of phosphate buffer saline (PBS; pH = 7.4) solution containing 200 ng/mL 
of VEGF-R1 ECD/Fc chimera (R&D Systems, UK). The plate was sealed and incubated 
overnight at 4°C. After 3 washes with 250 μl of PBS 0.5% (v/v) Tween 20 (Buffer A), the 
plate was blocked by adding 200 µl of PBS with 2% (w/v) bovine serum albumin fraction IV 
(BSA; Sigma-Aldrich, France) and agitated at 25°C for 2 hours. The plate was washed 
carefully three times with buffer A. The plates were then ready for sample addition. 
Alternatively, the plates could be dried under vacuum, sealed with a drying agent and stored 
at 4°C for 1 week.  
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 Then, 100 µl of a solution of btVEGF165 (obtained as part of a Fluorokine biotinylated 
VEGF kit from R&D Systems, UK) diluted at varying concentrations in PBS were added to 
each well. The plate was sealed again and incubated 2,5 hours at 25°C. Three washes were 
performed with buffer A and 100 µl of AMDEX™ streptavidin-horse radish peroxydase 
(Amersham Biosciences, UK) diluted at 1:8000 in PBS containing 0.5% (v/v) Tween 20 and 
0.3% (w/v) BSA were added to each well. After 45 min incubation at 25°C under obscurity, 
the plate was washed 5 times with buffer A and 100 µl of SuperSignal west pico 
chemiluminescent substrate (Pierce, USA) were added. Luminescence was quantified with an 
EnVision™ 2101 Multilabel reader (Perkin Elmer, USA). Signal is given as relative light 
units (RLU). Non-specific binding is defined as the signal measured in the absence of 
receptor coated on the microplate. The specific binding was calculated as the difference 
between total binding and non-specific binding. Data were analyzed using the non-linear 
regression function in Prism® version 4.03 (GraphPad Software, USA).  
In a second step, to verify the specificity of the interaction, we realized a competition 
assay with unlabeled recombinant human VEGF165. The plate was coated with 20 ng/well of 
VEGF-R1 ECD, then blocked by BSA, and 50 µL of VEGF165 (Abcys, France) at various 
concentrations were added to 50 µL of btVEGF165 at 5 ng/mL (131 pM). After 2.5 h of 
incubation at 25°C, wells were washed three times with buffer A and the btVEGF165 
remaining was detected as previously described. The percentages of displacement were 
calculated by the following formula: Percentage of displacement = 100*[1-(S-NS)/(MS-NS)], 
where S refers to the signal measured, NS is the non specific binding signal and MS is the 
maximum binding signal obtained with btVEGF165 without competitor.  
The saturation curve is represented in figure 2 A. The binding capacity of btVEGF165 
reached its maximum when added at a concentration of 10 nM. Based on three independent 
experiments, the dissociation constant (Kd) was estimated at 750 pM, a value comparable to 
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the one found by Barleon et al. [11]. Considering that performing the assay with recombinant 
receptors does not allow to reproduce the favourable effect of membrane microenvironment 
existing in cell based assays, it is not surprising to obtain a value superior to the Kd 
previously described for VEGF165 interaction with Cos cells transfected with VEGF-R1 (10-
30 pM) [12]. In addition, our competition assay with unlabeled VEGF165 (Fig. 2 B) 
demonstrates that 50% of biotinylated ligand binding (introduced at 131pM) was inhibited by 
387 ± 60 pM of unlabeled VEGF165. This result proves that the btVEGF165 exhibits roughly 
the same affinity for VEGF-R1 ECD as unlabeled VEGF165.  
Another key point in developing a screening assay is the assessment of its robustness 
in the presence of dimethylsulfoxyde (DMSO). As a matter of fact, screening of chemical 
libraries is typically conducted in the presence of low concentrations of DMSO to avoid 
problems of solubility. We controlled that weak DMSO concentrations (0.63%, 1.25% and 
2.5% v/v) had no significant effect on btVEGF165 binding to VEGF-R1 ECD. The effect was 
more obvious at 5% and 10% DMSO, leading to respectively, 32% and 46% decrease of 
specific binding signals. Nevertheless, the reproducibility of the experiment performed on 
triplicate wells was not affected in all cases. Based on these data, a final concentration of 1% 
DMSO was chosen for development of the assay, allowing the screening of most of chemical 
compound libraries. 
It follows then that this assay represents a strong asset in the search of small-molecule 
ligands of VEGF-R1. Thus, we verified that molecules exhibiting a weak affinity for the 
receptor could be readily identified using this screening test. Therefore, we evaluated the 
affinity of peptides previously described in the literature as ligands of VEGF receptors (Fig. 2 
B). Peptides were synthesized by solid phase peptide synthesis on an Applied Biosystems 
433A synthesizer (Applied Biosystems, USA) using Fmoc chemistry. They were purified to 
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at least 95% purity by semi-preparative reverse phase HPLC and their identity was confirmed 
by electron spray MS (LCQ Advantage, Thermo Electron Corporation, USA).  
QK (Ac-KLTWQELYQLKYKGI-NH2) is a VEGF mimicking peptide [8], exhibiting 
an agonist activity for VEGF receptors. Its affinity was determined by competition with 
[125I]VEGF165 for the binding sites of VEGF on cell membranes isolated from bovine aorta 
endothelial cells which express VEGF-R1, VEGF-R2 and NP-1 receptors. This assay leads to 
an IC50 estimated in the nanomolar range. Tested on our screening assay, its IC50 for VEGF-
R1 was measured at 32 µM. Based on this result, it can be hypothesized that the high affinity 
of QK for endothelial cells may be triggered essentially by its binding to VEGF-R2/NP-1.  
SP5.2 (NGYEIEWYSWVTHGMY-NH2) has been described as a VEGF-R1 specific 
antagonist peptide, identified by phage display library screening [13]. To evaluate its affinity 
for the receptor, El-Mousawi et al. synthesized a fluorescein-labeled SP5.2 peptide and 
measured the fluorescence signal due to peptide binding to immobilized VEGF-R1/Fc 
chimera (1 µg/well) in a saturation assay. Based on this experiment, SP5.2 binding was dose-
dependent, with a half-maximum value at 40 µM. This in vitro value on purified receptor is 
in the same order of magnitude than the IC50 obtained for SP5.2 in our chemiluminescent 
competition assay, measured at 28 ± 7 µM.  
As a negative control, we chose the peptide A7R (ATWLPPR) initially described as a 
VEGF-R2 specific antagonist and which recently proved to be a NP-1 specific ligand [7, 10, 
14]. As expected, no displacement of btVEGF165 was observed in the range of concentrations 
tested (3-100 µM). 
Finally, we verified if the screening assay could allow the identification of larger 
inhibitors of VEGF165. Thus, we tested a monoclonal antibody raised again VEGFR-1 ECD 
(anti-VEGFR-1, clone FLT-19, Sigma-Aldrich). This antibody proved to be able to displace 
btVEGF165 binding to VEGFR-1 with an IC50 of 2.81 ± 1.59 nM (supplementary data). 
 6
H
AL author m
anuscript    inserm
-00168674, version 1
In summary, the current study describes a method for identifying ligands of VEGF 
receptor 1 based on chemiluminescent detection of biotinylated VEGF165 binding to the 
recombinant receptor. This assay has been developed on an easy to handle 96-well format. 
Considering the small amounts of proteins used and the suppression of radioactivity issues, 
this assay represents an interesting progress for the evaluation of new VEGF-R1 ligands and 
should allow the screening of chemical libraries, even by academic institutions. 
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Fig. 1. Schematic representation of the chemiluminescent screening assay. 
  
 
 
Fig. 2. (A) Solid-phase binding assay of biotinylated VEGF165 to recombinant human VEGF-
R1. Total and non-specific binding curves correspond to the signal observed, respectively in 
presence (20 ng/well) or in absence of VEGF-R1. The data show mean numbers from 
triplicate wells. Error bars represent for standard deviation. (B) Competition assay between 
human VEGF165 and biotinylated VEGF165 (5 ng/mL; 131 pM) for binding to VEGF-R1 ECD 
(20 ng/well). Data is presented as a percentage of displacement of biotinylated VEGF165. (C) 
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Competition assay between peptides QK, SP5.2 and A7R and btVEGF165 in presence of 1% 
DMSO. 
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